Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurosurg Clin N Am. 2010 Jan;21(1):139-57. doi: 10.1016/j.nec.2009.09.005.

Dendritic cell vaccines for brain tumors.

Author information

1
UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS 74-145, Los Angeles, CA 90095-6901, USA.

Abstract

Over the past decade, dendritic cell-based immunotherapy for central nervous system tumors has progressed from preclinical rodent models and safety assessments to phase I/II clinical trials in over 200 patients, which have produced measurable immunologic responses and some prolonged survival rates. Many questions regarding the methods and molecular mechanisms behind this new treatment option, however, remain unanswered. Results from currently ongoing and future studies will help to elucidate which dendritic cell preparations, treatment protocols, and adjuvant therapeutic regimens will optimize the efficacy of dendritic cell vaccination. As clinical studies continue to report results on dendritic cell-mediated immunotherapy, it will be critical to continue refining treatment methods and developing new ways to augment this promising form of glioma treatment.

PMID:
19944973
PMCID:
PMC2810429
DOI:
10.1016/j.nec.2009.09.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center